A Tool to Design Bridging Oligos Used to Detect Pseudouridylation Sites on RNA after CMC Treatment.

Baptiste Bogard, Gilles Tellier, Claire Francastel, Florent Hubé

Abstract read

In one paragraph

Article in Non-coding RNA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Baptiste BogardUMR7216 Épigénétique et Destin Cellulaire, CNRS, Université Paris Cité, F-75013 Paris, France.

Gilles TellierUMR7216 Épigénétique et Destin Cellulaire, CNRS, Université Paris Cité, F-75013 Paris, France.

Claire FrancastelUMR7216 Épigénétique et Destin Cellulaire, CNRS, Université Paris Cité, F-75013 Paris, France.ORCID 0000-0002-6353-4320

Florent HubéUMR7216 Épigénétique et Destin Cellulaire, CNRS, Université Paris Cité, F-75013 Paris, France.ORCID 0000-0001-7560-2530

Funding

Agence Nationale de la Recherche ANR-11-LABX-0071Agence Nationale de la Recherche ANR-17-EURE-0013Agence Nationale de la Recherche ANR-18-IDEX-0001Agence Nationale de la Recherche #ANR-19-CE12-0022French Muscular Dystrophy Association 22341

6 · The paper itself

Abstract

Pseudouridylation is one of the most abundant modifications found in RNAs. To identify the Pseudouridylation sites (Psi) in RNAs, several techniques have been developed, but the most common and robust is the CMC (N-cyclohexyl-N'-(2-morpholinoethyl)carbodiimide) treatment, which consists in the addition of an adduct on Psi that inhibits the reverse transcription. Here, we describe a turnkey method and a tool to design the bridging oligo (DBO), which is somewhat difficult to design. Finally, we propose a trouble-shooting guide to help users.

Indexed as

CMC treatmentOligonucleotide designPseudouridylationsnoRNAtool

Identifiers

PMID36287115

DOI10.3390/ncrna8050063

PMCPMC9610020

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.